Product Description: A 438079 is a potent, and selective?P2X7 receptor?antagonist with?pIC50?of 6.9.
Applications: Neuroscience-Neuromodulation
Formula: C13H9Cl2N5
Citations: Brain, Behavior, and Immunity. 2020 Aug;88:507-514./Front Mol Neurosci. 2018 Nov 6;11:401./Gen Physiol Biophys. 2019 Sep;38(5):407-416./Inflammation. 2024 Aug 17./Int J Mol Sci. 2022 May 17;23(10):5586./J Adv Res. 2024 Jul 15:S2090-1232(24)00298-4./Med Sci Monit. 2020 Sep 21;26:e925491. /Neural Regen Res. 2021 Aug;16(8):1582-1591./Purinergic Signal. 2023 Mar 1./Purinergic Signal. 2024 Nov 16./Cancer Immunol Res. 2020 Nov;8(11):1426-1439./J Ethnopharmacol. 2024 Sep 7:118792./J Immunol. 2023 May 5;ji2200838.
References: [1]McGaraughty S, et al. P2X7-related modulation of pathological nociception in rats. Neuroscience. 2007 Jun 8;146(4):1817-28./[2]Mesuret G, et al. CNS Neurosci Ther. 2014 Jun;20(6):556-64./[3]Marcellino D, et al. On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079. J Neural Transm (Vienna). 2010 Jun;117(6):681-7./[4]Martins JP, et al. The role of P2X7 purinergic receptors in inflammatory and nociceptive changes accompanying cyclophosphamide-induced haemorrhagic cystitis in mice. Br J Pharmacol. 2012 Jan;165(1):183-96.
CAS Number: 899507-36-9
Molecular Weight: 306.15
Compound Purity: 99.88
Research Area: Neurological Disease
Solubility: DMSO : 100 mg/mL (ultrasonic)/H2O : 0.2 mg/mL (ultrasonic)
Target: P2X Receptor
Deutsch
English
